Biochemical markers of bone turnover in patients with localized and metastasized prostate cancer

BJU International

Volumn 99, Issue 2, 2007, Pages 330-334

  Hegele, Axel ^a   Wahl, Hans Günther ^a   Varga, Zoltan ^a   Sevinc, Selim ^a   Koliva, Liseta ^a   Schrader, Andres Jan ^a   Hofmann, Rainer ^a   Olbert, Peter ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Adjuvant therapy; Bisphosphonates; Bone metabolism; Bone metastases; Markers

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE; BIOCHEMICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; OSTEOCALCIN;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; BONE METASTASIS; BONE TURNOVER; CANCER STAGING; COMPARATIVE STUDY; CONTROLLED STUDY; HISTOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; METASTASIS; OSSIFICATION; OSTEOLYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RADICAL RETROPUBIC PROSTATECTOMY; URINARY TRACT DISEASE;

ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; BONE RESORPTION; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 33846213230     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06604.x     Document Type: Article

References (30)

1. Kataja VV, Bergh J. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of prostate cancer. Ann Oncol 2005; 16 (Suppl. 1): i34-6
2. Pfeilschifter J, Diel IJ. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol 2000; 18: 1570-93
3. Hussain SA, Weston R, Stephenson RN, George E, Parr NJ. Immediate dual energy X-ray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipulation. BJU Int 2003; 92: 690-4
4. Weinfurt KP, Li Y, Castel LD et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 2005; 16: 579-84
5. Oefelein MG, Ricchiuti V, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 2002; 168: 1005-7
6. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001; 27: 165-76
7. Boccon-Gibod L. Monitoring and treating the patient after radical treatment of localized prostate cancer. Eur Urol 1994; 20: 154-9
8. Kattan MW, Stapleton AM, Wheeler TM, Scardino PT. Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma. Cancer 1997; 79: 528-37
9. Dotan ZA, Bianco FJ, Scardino PT et al. Predicting time to metastatic progression from biochemical recurrence after radical prostatectomy. J Urol 2005; 173 (Suppl. 4): 309
10. Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J. The use of biochemical markers of bone turnover in osteoporosis. Osteoporos Int 2000; 11 (Suppl. 6): S2-17
11. Seibel MJ. Molecular markers of bone turnover: biochemical, technical and analytical aspects. Osteoporos Int 2000; 11 (Suppl. 6): S18-29
12. Fohr B, Dunstan CR, Seibel MJ. Clinical review 165: markers of bone remodeling in metastatic bone disease. J Clin Endocrinol Metab 2003; 88: 5059-75
13. Jung K, Lein M, Stephan C et al. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer 2004; 111: 783-91
14. Koeneman KS, Kao C, Ko SC et al. Osteocalcin-directed gene therapy for prostate-cancer bone metastasis. World J Urol 2000; 18: 102-10
15. Janckila AJ, Takahashi K, Sun SZ, Yam LT. Tartrate-resistant acid phosphatase isoform 5b as serum marker for osteoclastic activity. Clin Chem 2001; 47: 74-80
16. Woitge HW, Pecherstorfer M, Li Y et al. Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices. J Bone Miner Res 1999; 14: 792-801
17. Wittekind C, Meyer HJ, Bootz F eds., TNM Klassifikation Maligner Tumoren, 6th edn. Berlin, Heidelberg, New York: Springer, 2003
18. Schmidt-Gayk H, Spanuth E, Kotting J et al. Performance evaluation of automated assays for beta-CrossLaps, NMID-Osteocalcin and intact parathyroid hormone (BIOROSE Multicenter Study). Clin Chem Lab Med 2004; 42: 90-5
19. O'Sullivan JM, Cook GJ. A review of the efficacy of bone scanning in prostate and breast cancer. Q J Nucl Med 2002; 46: 152-9
20. Wymenga LF, Boomsma JH, Groenier K, Piers DA, Mensink HJ. Routine bone scans in patients with prostate cancer related to serum prostate-specific antigen and alkaline phosphatase. BJU Int 2001; 88: 226-30
21. Garnero P. Markers of bone turnover in prostate cancer. Cancer Treat Rev 2001; 27: 187-92
22. Brown JE, Cook RJ, Major P et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005; 97: 59-69
23. Hannon R, Eastell R. Preanalytical variability of biochemical markers of bone turnover. Osteoporos Int 2000; 11 (Suppl. 6): S30-44
24. Roudier MP, Vesselle H, True LD et al. Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results. Clin Exp Metastasis 2003; 20: 171-80
25. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352: 154-64
26. Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000; 163: 181
27. Daneshmand S, Quek ML, Stein JP et al. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long term results. J Urol 2004; 172: 2252-5
28. Messing E, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with lymph node positive prostate cancer. Results at 10 years of EST 3886. J Urol 2003; 169: 396
29. Corey E, Brown LG, Quinn JE et al. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res 2003; 9: 295-306
30. Dumon JC, Journe F, Kheddoumi N, Lagneaux L, Body JJ. Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cells. Eur Urol 2004; 45: 521-9